This is really excellent news, and, as the article points out, evidence has been accruing that even a single dose of HPV vaccine may be enough for durable and highly effective prevention of cervical cancer.
https://www.statnews.com/2025/04/28/hpv-vaccine-single-dose-prevents-infection-just-as-well-as-two-doses-hci-clinical-trial/
https://www.statnews.com/2025/04/28/hpv-vaccine-single-dose-prevents-infection-just-as-well-as-two-doses-hci-clinical-trial/
Comments
Also, while Lowy at NCI was certainly a key inventor of the vaccine, there were 3 other labs who contributed independently: Georgetown, the University of Rochester, and the University of Queensland.
https://www.sciencedirect.com/science/article/abs/pii/S0264410X20315644
That was GSK’s rationale to include a TLR4 agonist adjuvant, which is the bivalent vaccine in this review, vs the 4(+5) Merck vaccine on alum.
More antigens wins!